Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from SST but had better survival with ipilimumab-based regimens or targeted therapy compared with anti-PD-1 monotherapy.
Authors
- Michele Del Vecchio (ORCID: https://orcid.org/0000-0001-9060-2512)
- Marcus O. Butler (ORCID: https://orcid.org/0000-0002-9840-7057)
- Ana Arance (ORCID: https://orcid.org/0000-0003-2896-1957)
- Mario Mandalà (ORCID: https://orcid.org/0000-0001-8846-8959)
- Luis de la Cruz‐Merino (ORCID: https://orcid.org/0000-0002-5333-0535)
- Andrew F. Hill (ORCID: https://orcid.org/0000-0001-5581-2354)
- Leslie A. Fecher (ORCID: https://orcid.org/0000-0002-6534-7457)
- C. Lance Cowey (ORCID: https://orcid.org/0000-0001-8597-8486)
- Michael Schenker (ORCID: https://orcid.org/0000-0003-2645-6391)
- Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
- Vanna Chiarion‐Sileni (ORCID: https://orcid.org/0000-0001-9191-9124)
- Petr Arenberger (ORCID: https://orcid.org/0000-0002-4800-5877)
- Jeffrey S. Weber (ORCID: https://orcid.org/0000-0002-4962-2957)
- Nikhil I. Khushalani (ORCID: https://orcid.org/0000-0002-3636-4143)
- Maurice Lobo (ORCID: https://orcid.org/0009-0008-4674-6744)
- Jean‐Jacques Grob (ORCID: https://orcid.org/0000-0002-0667-153X)
- Iván Márquez‐Rodas (ORCID: https://orcid.org/0000-0002-2476-668X)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Paola Queirolo (ORCID: https://orcid.org/0000-0002-9917-6633)
- Stéphane Dalle (ORCID: https://orcid.org/0000-0002-3423-4548)
- James Larkin (ORCID: https://orcid.org/0000-0001-5569-9523)
- Margarita Askelson (ORCID: https://orcid.org/0000-0001-9133-7693)
- Michael Millward (ORCID: https://orcid.org/0000-0002-1744-1617)
- Helen J Gogas (ORCID: https://orcid.org/0000-0002-0451-2885)
- Victoria Atkinson
- Anna Maria Di Giacomo
Institutions
- University of Siena (IT)
- The University of Sydney (AU)
- Royal Marsden NHS Foundation Trust (GB)
- The University of Queensland (AU)
- The University of Western Australia (AU)
- University of Toronto (CA)
- National and Kapodistrian University of Athens (GR)
- Charles University (CZ)
- Aix-Marseille Université (FR)
- University of Michigan (US)
- Royal North Shore Hospital (AU)
- Texas Oncology (US)
- Sir Charles Gairdner Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- Hospital General Universitario Gregorio Marañón (ES)
- Moffitt Cancer Center (US)
- NYU Langone Health (US)
- Hospital Universitario Virgen Macarena (ES)
- Bristol-Myers Squibb (United States) (US)
- Hospices Civils de Lyon (FR)
- Ospedale Papa Giovanni XXIII (IT)
- Istituto Oncologico Veneto (IT)
- Hospital Clínic de Barcelona (ES)
- Melanoma Institute Australia (AU)
- Trans Tasman Radiation Oncology Group (AU)
- Gallipoli Medical Research Foundation (AU)
- Instituto de Biomedicina de Sevilla (ES)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University Hospital Kralovske Vinohrady (CZ)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Hôpital de la Timone (FR)
- European Institute of Oncology (IT)
- Universidad de Sevilla (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1200/jco.23.01448
- Citations
- 7
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Array BioPharma
- AtriCure
- Regeneron Pharmaceuticals
- Celldex Therapeutics
- Five Prime Therapeutics
- BeiGene
- Apollomics
- Relay Therapeutics
- Seagen
- Astellas Pharma
- Ono Pharmaceutical
- Genentech
- EMD Serono